Annual CFI
-$117.17 M
+$178.83 M+60.42%
December 31, 2023
Summary
- As of February 8, 2025, XENE annual cash flow from investing activities is -$117.17 million, with the most recent change of +$178.83 million (+60.42%) on December 31, 2023.
- During the last 3 years, XENE annual CFI has fallen by -$100.35 million (-596.45%).
- XENE annual CFI is now -582.30% below its all-time high of $24.29 million, reached on December 31, 2017.
Performance
XENE Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
$1.98 M
-$108.74 M-98.21%
September 30, 2024
Summary
- As of February 8, 2025, XENE quarterly cash flow from investing activities is $1.98 million, with the most recent change of -$108.74 million (-98.21%) on September 30, 2024.
- Over the past year, XENE quarterly CFI has dropped by -$108.74 million (-98.21%).
- XENE quarterly CFI is now -98.21% below its all-time high of $110.72 million, reached on June 30, 2024.
Performance
XENE Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
-$179.08 M
-$51.90 M-40.81%
September 30, 2024
Summary
- As of February 8, 2025, XENE TTM cash flow from investing activities is -$179.08 million, with the most recent change of -$51.90 million (-40.81%) on September 30, 2024.
- Over the past year, XENE TTM CFI has dropped by -$51.90 million (-40.81%).
- XENE TTM CFI is now -256.99% below its all-time high of $114.07 million, reached on September 30, 2023.
Performance
XENE TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
XENE Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +60.4% | -98.2% | -40.8% |
| 3 y3 years | -596.5% | -92.9% | -3.0% |
| 5 y5 years | -304.2% | -92.9% | -3.0% |
XENE Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +60.4% | -98.2% | +100.8% | -257.0% | +64.0% |
| 5 y | 5-year | -596.5% | +60.4% | -98.2% | +100.8% | -257.0% | +64.0% |
| alltime | all time | -582.3% | +60.4% | -98.2% | +100.8% | -257.0% | +64.0% |
Xenon Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $1.98 M(-98.2%) | -$179.08 M(+40.8%) |
| Jun 2024 | - | $110.72 M(-339.6%) | -$127.18 M(-39.4%) |
| Mar 2024 | - | -$46.20 M(-81.2%) | -$209.99 M(+79.2%) |
| Dec 2023 | -$117.17 M(-60.4%) | -$245.57 M(-555.8%) | -$117.17 M(-202.7%) |
| Sep 2023 | - | $53.88 M(+93.1%) | $114.07 M(-165.6%) |
| Jun 2023 | - | $27.90 M(-40.2%) | -$173.91 M(-13.3%) |
| Mar 2023 | - | $46.62 M(-425.2%) | -$200.49 M(-32.3%) |
| Dec 2022 | -$296.00 M(+20.0%) | -$14.34 M(-93.9%) | -$296.00 M(-40.5%) |
| Sep 2022 | - | -$234.10 M(<-9900.0%) | -$497.10 M(+100.9%) |
| Jun 2022 | - | $1.32 M(-102.7%) | -$247.43 M(+2.9%) |
| Mar 2022 | - | -$48.89 M(-77.3%) | -$240.55 M(-2.5%) |
| Dec 2021 | -$246.77 M(+1366.8%) | -$215.43 M(-1483.2%) | -$246.77 M(-2180.3%) |
| Sep 2021 | - | $15.57 M(+90.1%) | $11.86 M(-154.6%) |
| Jun 2021 | - | $8.19 M(-114.9%) | -$21.75 M(+14.4%) |
| Mar 2021 | - | -$55.10 M(-227.6%) | -$19.00 M(+13.0%) |
| Dec 2020 | -$16.82 M(-74.6%) | $43.20 M(-339.6%) | -$16.82 M(-86.0%) |
| Sep 2020 | - | -$18.03 M(-264.9%) | -$120.34 M(+27.3%) |
| Jun 2020 | - | $10.93 M(-120.7%) | -$94.57 M(-15.7%) |
| Mar 2020 | - | -$52.92 M(-12.3%) | -$112.13 M(+69.4%) |
| Dec 2019 | -$66.21 M(+128.4%) | -$60.32 M(-879.3%) | -$66.21 M(+258.9%) |
| Sep 2019 | - | $7.74 M(-216.8%) | -$18.45 M(-62.8%) |
| Jun 2019 | - | -$6.63 M(-5.4%) | -$49.53 M(+20.9%) |
| Mar 2019 | - | -$7.00 M(-44.2%) | -$40.97 M(+41.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$28.99 M(-219.3%) | -$12.56 M(-46.2%) | -$28.99 M(+172.7%) |
| Sep 2018 | - | -$23.35 M(-1303.5%) | -$10.63 M(-184.1%) |
| Jun 2018 | - | $1.94 M(-61.0%) | $12.63 M(-36.9%) |
| Mar 2018 | - | $4.98 M(-14.2%) | $20.02 M(-17.6%) |
| Dec 2017 | $24.29 M(-150.8%) | $5.80 M(-6620.2%) | $24.29 M(-276.9%) |
| Sep 2017 | - | -$89.00 K(-101.0%) | -$13.73 M(-0.2%) |
| Jun 2017 | - | $9.33 M(+0.9%) | -$13.76 M(-64.3%) |
| Mar 2017 | - | $9.25 M(-128.7%) | -$38.51 M(-19.5%) |
| Dec 2016 | -$47.84 M(-569.3%) | -$32.23 M(>+9900.0%) | -$47.84 M(+203.6%) |
| Sep 2016 | - | -$111.00 K(-99.3%) | -$15.76 M(+127.1%) |
| Jun 2016 | - | -$15.42 M(>+9900.0%) | -$6.94 M(-180.5%) |
| Mar 2016 | - | -$83.00 K(-42.0%) | $8.62 M(-15.4%) |
| Dec 2015 | $10.19 M(-414.2%) | -$143.00 K(-101.6%) | $10.19 M(-10.4%) |
| Sep 2015 | - | $8.71 M(+6256.9%) | $11.38 M(-515.1%) |
| Jun 2015 | - | $137.00 K(-90.8%) | -$2.74 M(+93.7%) |
| Mar 2015 | - | $1.49 M(+43.4%) | -$1.42 M(-56.4%) |
| Dec 2014 | -$3.24 M(-71.7%) | $1.04 M(-119.2%) | -$3.24 M(-24.3%) |
| Sep 2014 | - | -$5.41 M(-469.7%) | -$4.28 M(-480.8%) |
| Jun 2014 | - | $1.46 M(-532.8%) | $1.13 M(-432.8%) |
| Mar 2014 | - | -$338.00 K | -$338.00 K |
| Dec 2013 | -$11.47 M(-2436.5%) | - | - |
| Dec 2012 | $491.00 K(-96.5%) | - | - |
| Dec 2011 | $13.89 M | - | - |
FAQ
- What is Xenon Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals annual CFI year-on-year change?
- What is Xenon Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals quarterly CFI year-on-year change?
- What is Xenon Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals TTM CFI year-on-year change?
What is Xenon Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of XENE is -$117.17 M
What is the all time high annual CFI for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high annual cash flow from investing activities is $24.29 M
What is Xenon Pharmaceuticals annual CFI year-on-year change?
Over the past year, XENE annual cash flow from investing activities has changed by +$178.83 M (+60.42%)
What is Xenon Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of XENE is $1.98 M
What is the all time high quarterly CFI for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high quarterly cash flow from investing activities is $110.72 M
What is Xenon Pharmaceuticals quarterly CFI year-on-year change?
Over the past year, XENE quarterly cash flow from investing activities has changed by -$108.74 M (-98.21%)
What is Xenon Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of XENE is -$179.08 M
What is the all time high TTM CFI for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high TTM cash flow from investing activities is $114.07 M
What is Xenon Pharmaceuticals TTM CFI year-on-year change?
Over the past year, XENE TTM cash flow from investing activities has changed by -$51.90 M (-40.81%)